ADA: Metsera asset data support Pfizer’s ‘entry point’ into obesity market

Pfizer's Berobenatide Shows Robust Phase 2b Weight Loss Data

Pfizer presented positive Phase 2b data for berobenatide (from Metsera) at the 2026 American Diabetes Association meeting. The GLP-1 agonist demonstrated robust weight loss across three studies (VESPER-1, -2, -3) in patients with obesity or overweight, with or without diabetes. Key findings included a 15.9% weight reduction at 32 weeks in VESPER-1's extension phase and a 14.9% drop at 60 weeks for a monthly dose subgroup. The drug also showed a manageable safety and tolerability profile, comparable to its class, supporting its advancement into a broad Phase 3 program. This data bolsters Pfizer's $10 billion investment in Metsera and positions berobenatide as a potential monthly injection option in the competitive obesity market.

• Efficacy Data from VESPER-1 and VESPER-2: The Phase 2b VESPER-1 study showed a non-placebo-adjusted 15.9% reduction in weight at 32 weeks into its open-label extension phase. Separately, VESPER-2, which tested weekly dosing regimens in patients with obesity/overweight and type 2 diabetes, demonstrated up to 10.2% weight reduction at week 28 with the highest weekly maintenance dose. These results were noted by analysts to compare favorably to tirzepatide, supporting Pfizer's broader development plan for berobenatide.
• Potential for Monthly Dosing and Future Strategy: A subgroup in VESPER-1 treated with 4.8-mg berobenatide once-monthly achieved a 14.9% drop in weight at 60 weeks versus baseline, highlighting the drug's potential as a monthly injection. Pfizer plans a broad Phase 3 program, intending to first launch berobenatide as a weekly medicine, with a monthly injection to follow as a maintenance option in 2029, contingent on Phase 3 results expected in 2028.
• Safety and Tolerability Profile: Data from the VESPER-3 study, focusing on patients without type 2 diabetes, indicated a safety and tolerability profile on par with the GLP-1 drug class. Discontinuation rates due to treatment-emergent adverse events (TEAEs) in VESPER-3 ranged from 11.1% to 20.8% across different doses, with an overall 9.3% across berobenatide arms. Analysts deemed this profile "manageable" and supportive of further development in Phase 3 studies, especially with planned dosing flexibility.

Berobenatide's Promising Phase 2b Efficacy and Safety at ADA

Recent comprehensive analyses have examined several promising therapeutic approaches for obesity management across diverse patient populations. The Tirzepatide for adults living with obesity (2025) study evaluated this dual GIP/GLP-1 receptor agonist administered as weekly injections ranging from 5-15 mg. At medium-term follow-up (12-18 months), tirzepatide demonstrated substantial efficacy with a mean weight reduction of 16.03% from baseline and significantly increased the proportion of patients achieving clinically meaningful 5% weight loss (risk ratio 3.60). Long-term data at 3.5 years showed sustained weight reduction of 15.66%, indicating durability of response. Safety analysis revealed increased non-serious adverse events but little difference in serious adverse events, mortality, or major adverse cardiovascular events compared to placebo.

The Network meta-analyses of GLP-1 receptor agonists for weight loss (2025) provided comparative effectiveness data across multiple agents in this therapeutic class. Subcutaneous tirzepatide achieved the most substantial weight loss, ranging from 9 kg at 5 mg to 12 kg at 15 mg doses at 6 months. Subcutaneous semaglutide 2.4 mg demonstrated weight loss between 11.5-12.5 kg over the same timeframe. Updated analyses confirmed tirzepatide's superiority over semaglutide at the 15 mg dose, though lower tirzepatide doses showed comparable efficacy. Safety profiles indicated that the most effective agents for weight loss were generally associated with increased safety risks compared to placebo, consistent with the class effect of GLP-1-based therapies.

Beyond pharmacological interventions, The effect of obesity interventions on male fertility (2025) study examined lifestyle modifications, pharmacotherapy with metformin and liraglutide, and bariatric surgery in male patients with obesity. Lifestyle interventions combining healthy diet and exercise showed meaningful improvements in sperm parameters, including enhanced normal morphology (mean difference 0.59%) and progressive motility (10.56%). Bariatric surgery demonstrated no clinically significant changes in semen parameters or DNA damage, while pharmacotherapy data remained insufficient for definitive conclusions regarding fertility outcomes. These findings highlight the multifaceted benefits of obesity treatment extending beyond weight loss to reproductive health considerations.

Berobenatide's Competitive Edge in the Evolving Obesity Market

Recent evidence demonstrates that investigational obesity therapies are increasingly challenging established standard-of-care treatments through superior efficacy profiles and novel mechanisms of action. The most significant advancement comes from next-generation GLP-1 receptor agonists, dual and triple incretin agonists, and amylin-based combination therapies, with some agents inducing 15-25% weight loss that approaches outcomes once exclusive to bariatric surgery. This paradigm shift is particularly evident when comparing newer agents like semaglutide and tirzepatide, which showed outstanding weight-loss effects in multinational phase III trials, against traditional FDA-approved medications such as orlistat (2.9% placebo-subtracted weight reduction), naltrexone/bupropion (4.0%), and liraglutide (5.4%).

Innovative combination approaches are demonstrating promising differentiation from monotherapy standards. The investigational triple combination NS-0200 (leucine, metformin, and sildenafil) achieved dose-responsive weight reduction of 2.4 kg in the full cohort and 5.0 kg in high-triglyceride patients, while simultaneously improving multiple comorbidities in 54% of high-dose subjects versus only 5% of placebo subjects. Similarly, novel selective androgen receptor modulators like GTx-024 (enobosarm) showed dose-dependent increases in lean body mass with significant improvements in physical function and insulin resistance, representing a fundamentally different therapeutic approach compared to traditional weight-loss medications that primarily focus on appetite suppression or nutrient absorption.

The evolving treatment landscape suggests a shift toward more stepwise, pharmacotherapy-first approaches, particularly for patients with BMI 30-40 kg/m², challenging existing bariatric surgery criteria established during an era of limited medical alternatives. Cost-effectiveness analyses support this transition, with studies showing that while bariatric surgery remains cost-effective for BMI >35 kg/m² patients, the superior efficacy of newer pharmacotherapies may justify medical intervention at lower BMI thresholds. However, the heterogeneous nature of obesity and wide patient-to-patient variability in treatment response necessitates individualized care approaches, as there remains no reliable method to predict which anti-obesity medication will be most effective for a given patient without empirical trial.